Arrowhead Q2 net income $48.7M ($0.45 diluted); milestones from Takeda, GSK, positive ARO-RAGE data

ARROWHEAD PHARMACEUTICALS, INC.

2023-Q2 EPS reported $0.07 revenue$208,813,000

Revenue $146.3M, operating income $48.2M, net income $48.7M ($0.45 diluted), up from $44.4M ($0.41) in prior year.
Earned $40M milestone from Takeda for fazirsiran Phase 3 start; $30M from GSK for Phase 2b of GSK4532990 (NASH).
Phase 1/2 ARO-RAGE: mean max 80% reduction in serum sRAGE after two 92 mg doses; no serious AEs; supports lung delivery platform.
Regained rights to ARO-PNPLA3 from Janssen; FDA Fast Track for ARO-APOC3 for familial chylomicronemia syndrome.
Cash and investments $559.8M vs $482.3M at Sept 30, 2022; R&D Day June 1, 2023; ARO-SOD1 on track for Q3 CT filing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. reported its fiscal second quarter ended March 31, 2023 results: revenue $ 146,267, net income $ 48,675, EPS $ 0.45.

Period: its fiscal second quarter ended March 31, 2023
Revenue: $ 146,267
Net income: $ 48,675
EPS: $ 0.45
Result: reported results

Exact text from the filing

in The New England Journal of Medicine Selected Fiscal 2023 Second Quarter Financial Results Three Months Ended March 31, OPERATING SUMMARY 2023 2022 (unaudited) Revenue $ 146,267 $ 151,805 Operating Expenses: Research and development 74,881 75,985 General and administrative expenses 23,221 34,267 Total Operating Expenses 98,102 110,252 Operating income

View on SEC.gov

Browse all earnings releases →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-014859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.